Amicus Therapeutics (NASDAQ:FOLD) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a research note published on Saturday morning.

Several other analysts have also weighed in on the company. Guggenheim upped their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Cantor Fitzgerald upped their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Finally, Morgan Stanley decreased their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Trading Down 1.4 %

Shares of FOLD stock opened at $9.52 on Friday. Amicus Therapeutics has a 1 year low of $9.02 and a 1 year high of $14.57. The firm has a market capitalization of $2.84 billion, a PE ratio of -28.00 and a beta of 0.68. The stock has a fifty day moving average of $10.92 and a two-hundred day moving average of $10.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,398,532.40. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 30,401 shares of company stock worth $352,038. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Amicus Therapeutics by 20.1% during the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after buying an additional 2,307,385 shares in the last quarter. William Blair Investment Management LLC increased its holdings in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after buying an additional 1,477,084 shares during the period. Geode Capital Management LLC raised its stake in shares of Amicus Therapeutics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after buying an additional 80,926 shares in the last quarter. Finally, Fiera Capital Corp lifted its holdings in shares of Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after acquiring an additional 58,113 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.